Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences Announces Preclinical Data Showing SVP-Rapamycin’s Potential Benefit in Treatment of Pompe Disease

WATERTOWN, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious...
February 06, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine and Celiac Disease Treatment

WATERTOWN, Mass., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune...
January 31, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences to Participate in Two Investor Conferences in February

WATERTOWN, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune...
December 07, 2016 08:00 ET | Source: Selecta Biosciences Inc

Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit

SEL-212 Designed to be First Non-Immunogenic Uricase Therapeutic for Severe GoutData Show Substantial and Sustained Reduction of Serum Uric Acid Levels for 30 Days or Longer After Single Dose...
December 05, 2016 07:05 ET | Source: Selecta Biosciences Inc

Selecta Biosciences to Host Conference Call Today at 9:00 a.m. ET to Discuss License Agreement with Spark Therapeutics

WATERTOWN, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific...
November 10, 2016 07:00 ET | Source: Selecta Biosciences Inc

Selecta Biosciences Announces Third Quarter 2016 Financial Results and Provides Corporate Update

Phase 2 Trial of SEL-212 for Treatment of Gout InitiatedSEL-212 Phase 1 Clinical Data to be Presented December 7-8, 2016Preclinical Data Presented for SVP’s Potential in Gene Therapy and...
November 10, 2016 06:45 ET | Source: Selecta Biosciences Inc

Selecta Biosciences Receives Exclusive Rights to Peanut Allergy and Celiac Disease Programs

WATERTOWN, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune...
November 08, 2016 08:00 ET | Source: Selecta Biosciences Inc

Selecta Biosciences to Present at Two Upcoming Investor Conferences in November

WATERTOWN, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune...
November 03, 2016 08:00 ET | Source: Selecta Biosciences Inc

Selecta Biosciences to Report Third Quarter 2016 Financial Results on Thursday, November 10

WATERTOWN, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific...
October 31, 2016 08:00 ET | Source: Selecta Biosciences Inc

Selecta Biosciences Collaborators at the National Cancer Institute Present Preclinical Data Showing SVP-Rapamycin Application to Cancer Therapy

Data Underscore Potential of SVP-Rapamycin to Improve Therapeutic Benefit and Tolerability by Mitigating Unwanted Human Immune ResponsesResults Presented at the Immunogenicity and Bioassay Summit ...